GET DAILY SIGNALSLLY vs NVO: Lilly Maintains the Lead in the GLP-1 Market
Key Takeaways
- LLY has posted stronger relative performance, trading near record highs and repeatedly raising its 2026 revenue outlook, while NVO has lagged with shares well below prior peaks.
- Eli Lilly has widened its U.S. market-share lead in weight-loss and diabetes treatments, pressuring Novo Nordisk's core semaglutide franchise.
- Tickeron AI Verdict: Based on trend consistency, earnings momentum, and competitive positioning, Tickeron's AI currently favors LLY over NVO.
- For deeper context, explore LLY Major News and LLY Today's Price Move, as well as NVO Major News and NVO Today's Price Move.
- Discover how automated strategies are positioning across this market by exploring Trending AI Robots.
Introduction
Few rivalries in the pharmaceutical sector draw as much attention as the one between LLY (Eli Lilly and Company) and NVO (Novo Nordisk). Both firms are locked in direct competition within the fast-growing GLP-1 therapy space for diabetes and obesity. This comparison matters most to growth-focused investors and traders following the metabolic-health sector, where relative performance has diverged noticeably. By looking at recent momentum, business models, and market positioning, the goal is to clarify which name currently appears to have the stronger position.
LLY's Recent Momentum
Eli Lilly has stood out as one of the stronger large-cap healthcare performers lately. Its diabetes and obesity portfolio, led by Mounjaro and Zepbound, has fueled impressive growth. In the latest quarter, revenue rose about 39% year over year to roughly $24.4 billion, with Mounjaro sales climbing around 65% and Zepbound up nearly 50%. Management raised its full-year 2026 revenue guidance for the third time, moving the midpoint to a range of $91 billion to $92 billion. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Lilly's pipeline has added to investor confidence as well. Positive Phase 3 results showed its next-generation candidate retatrutide beating Novo Nordisk's Ozempic on blood-sugar control and weight loss in a direct diabetes study. Combined with a roughly 27% year-to-date gain and shares at record levels, the overall tone around LLY remains constructive.
NVO's Current Challenges
Novo Nordisk was the first to commercialize the GLP-1 category through Ozempic and Wegovy, yet recent share-price action reflects growing competitive pressure. The stock has fallen meaningfully over the past year and sits well below earlier peaks. At its Capital Markets Day in September, management laid out longer-term goals such as launching more than five blockbuster drugs and adding over $23 billion in new pipeline sales, but near-term details were limited and the stock declined afterward.
Additional headwinds include disappointing head-to-head results for the follow-up candidate CagriSema against Lilly's Zepbound, along with the upcoming patent cliff for the semaglutide franchise. The company now projects 2026 sales and operating profit ranging from flat to a mid-single-digit decline at constant exchange rates. As a result, NVO has moved from a high-growth narrative to one facing more questions.
Head-to-Head Comparison
The differences between the two companies stand out across several metrics. On growth, LLY continues to expand rapidly while NVO faces flat-to-declining revenue and pricing pressure. Lilly has taken an estimated 60% to 65% share of the U.S. weight-loss market, reducing Novo's earlier dominance.
Pipeline results also differ. Lilly's retatrutide has produced strong late-stage data, whereas Novo's CagriSema missed expectations in direct comparisons. On risk, Novo carries heavy concentration in semaglutide, which represents about three-quarters of sales ahead of patent expirations. Lilly carries a higher valuation and its own pricing pressures as realized prices decline. From what I see, current momentum and catalysts lean toward LLY, while NVO presents a lower entry valuation with more execution risk.
Tickeron AI Verdict
Looking at trend consistency, earnings momentum, competitive catalysts, and relative positioning, Tickeron's AI currently favors LLY over NVO. Lilly's record share prices, repeated upward guidance revisions, and positive clinical data point to more sustained positive momentum, whereas Novo's weaker relative performance and pipeline setbacks suggest greater uncertainty. This view is based on probabilistic analysis of present conditions rather than a firm forecast, and market dynamics can change with new information.
Exploring AI Tools for Market Context
In my own analysis, I occasionally reference Tickeron’s AI Trend Prediction Engine to gauge longer-term directional signals across names like these. It helps put short-term price moves into a broader probabilistic framework without replacing fundamental research.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LLY in upward trend: 10-day moving average broke above 50-day moving average on October 15, 2026
The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 51 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 62%.
The Moving Average Convergence Divergence (MACD) for LLY just turned positive on October 07, 2026. Looking at past instances where LLY's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +10.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 258 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
The Aroon Indicator entered an Uptrend today. In 233 of 297 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 78%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 11 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 55%.
LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 4 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 25 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 62 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (37.296) is slightly higher than the industry average of (-1.403). P/E Ratio (47.489) is within average values for comparable stocks, (21.451). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.039) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement